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Current research indicates that the nucleocapsid protein (NCp7) of human immunodeficiency virus type 1 (HIV-1) interacts
with a variety of RNA substrates during the progression of the viral life cycle. The RNA features specifically recognized by
the protein, however, have yet to be identified. SELEX was used to generate a set of RNAs whose affinities for nucleocapsid
were on the order of 2 1 1009 M. Comparative analysis revealed that each RNA contains a highly conserved fourteen
nucleotide sequence-block. Computer modeling and structure probing experiments indicate that the RNA ligands use the
consensus sequence to fold into hairpins with an identical asymmetric bulge. The presence of the nucleocapsid protein
protects the asymmetric bulge from ribonuclease attack, suggesting that it is the key element in protein recognition. A
search for similar structural motifs within the HIV genome reveals several potential interaction sites for the nucleocapsid
protein. q 1996 Academic Press, Inc.
INTRODUCTION with reverse transcriptase which influence strand trans-
fer and transcription rate (Weiss et al., 1992; Peliska et
One of the first events during the replication of HIV-1 al., 1994; Rodriguez-Rodriguez et al., 1995; Ji et al., 1996).
and all other known retroviruses is conversion of geno- Retroviral nucleocapsid proteins are precursor prod-
mic RNA to DNA using the viral reverse transcriptase ucts (Mervis et al., 1988; Morellet et al., 1992). HIV-1
(RT) and other host cell components (for review; Coffin, nucleocapsid protein contains two zinc finger binding
1982; Varmus and Brown, 1989; Wain-Hobson, 1994). The domains with the general structure Cys-X2-Cys-X4-His-
viral RNA is reverse transcribed by RT with a host tRNA X4-Cys (Gorelick et al., 1993). Mutations in each of these
being used as the primer (reviewed in Wong-Staal, 1990; finger domains result in different functional and structural
Vaishnav and Wong-Staal, 1991). Retroviral nucleocapsid defects (Gorelick et al., 1990, 1993; Julian et al., 1993).
proteins are intimately involved in annealing of the tRNA Similar types of mutations in RSV and MuLV nucleocap-
primer to the genomic RNA. It has been reported that sid proteins result in defects in RNA packaging and dimer
nucleocapsid proteins from Mason-Pfizer monkey virus formation (Me´ric and Spahr, 1986; Me´ric and Goff, 1989).
(MPMV) and HIV-1 facilitate primer annealing (Dib-Hajj Results from these studies suggest a role for the nucleo-
et al., 1993; Tsuchihashi and Brown, 1994; Lapadat-Ta- capsid protein during reverse transcription (Me´ric and
polsky et al., 1995). Moreover, it has been shown that Goff, 1989; Weiss et al., 1992) and possibly during infec-
the nucleocapsid proteins of Rous sarcoma virus (RSV) tion (Me´ric and Spahr, 1986).
and murine leukemia virus (MuLV) are directly involved Sequences near the 5* end of the mature HIV-1 viral
in annealing the tRNA primer onto the primer binding RNA are apparently involved in encapsidation (Aldovini
site under physiological conditions (Prats et al., 1988; and Young, 1990). It appears these sequences interact
Barat et al., 1989). NC proteins from the human immuno- specifically with the nucleic acid binding zinc finger do-
deficiency virus have also been implicated in dimeriza- mains of HIV-1 NC. Mutations in either of the two Zn//
tion of genomic RNA (Darlix et al., 1990; Sakaguchi et fingers or the encapsidation site result in similar defects.
al., 1993), encapsidation of full-length genomic RNA (Rizvi The 5* end of retroviral RNAs have been rigorously stud-
and Panganiban, 1993; South and Summers, 1993; Zhang ied and thus the structural and functional characteriza-
and Barklis, 1995; Tanchou et al., 1995), and interactions tion is extensive (Bender et al., 1978; Murti et al., 1981;
Darlix et al., 1982; Aldovini and Young, 1990; Harrison
and Lever, 1992; Surovoy et al., 1993).1 To whom correspondence and reprint requests should be ad-
Although HIV-1 nucleocapsid plays a crucial role in sodressed.
many different viral processes, the nature of its interac-2 Present address: NeXstar Pharmaceuticals, Inc., 2860 Wilderness
Place, Suite 200, Boulder, CO 80301. tion with substrate RNAs has yet to be clearly defined.
3060042-6822/96 $18.00
Copyright q 1996 by Academic Press, Inc.
All rights of reproduction in any form reserved.
AID VY 8230 / 6a21$$$521 10-16-96 03:37:06 viras AP: Virology
307RNA RECOGNITION BY HIV-1 NUCLEOCAPSID
To better understand the specific RNA features recog- through 8, 250 pmol of the selected RNA was used with
labeled RNA from that pool to follow the amount of recov-nized by the nucleocapsid protein, we used SELEX to
generate a set of RNA molecules with high affinity for ery. In each round, other than round 1, we selected about
3% of the total input RNA or a smaller fraction if countsthe HIV-1 protein. Sequence comparison and structural
characterization of the RNAs identified a consensus bind- were greater than 10-fold above the control (cpm bound
in the absence of protein). For rounds 9 and 10 we re-ing site of the nucleocapsid protein. A search of the HIV
genome for structures resembling the SELEX-generated duced the amount of RNA to 25 pmol. During the last 7
rounds (rounds 11–17), 25 pmol of cold-selected RNAconsensus revealed several potential targets for the
protein. was used along with 500 pmol of a nonamplifiable ran-
dom pool of competitor RNA as described (Allen et al.,
1995).MATERIALS AND METHODS
PCR amplification and selection Expression constructs
Amplification by PCR and the SELEX procedure were
The capsid–nucleocapsid (CA–NC) and nucleocapsidcarried out essentially as described (Tuerk and Gold,
(NC) segments of the HIV-1 gag protein were amplified1990). Five picomoles of a random pool of DNA oligomers
from the clone pBH10 (Ratner et al., 1985) and insertedwere used as template for PCR amplification for 8 cycles
downstream of the phage T7 promoter of the multicopyin the initial round. Complementary DNA of the selected
expression vector pGZ/H6, derived from the phagemidpool of RNA from subsequent rounds of SELEX was PCR
pTZ18R (Mead et al., 1986). The plasmid pGZ/H6CANC-amplified 18 cycles. PCR reactions were carried out in
6 expressed a fusion protein in which an N-terminal50-ml volumes containing 200 pmol of each primer, 2 mM
hexahistidine tag (MKLHHHHHHGY) was followed bydNTP’s, 5 units of Thermus aquaticus DNA polymerase
residues Gln127 through Asn432 of HIV-1 gag. The plas-(Perkin–Elmer–Cetus) in PCR buffer (10 mM Tris–Cl,
mid pGZ/NC55-1 expressed a 55-residue form of NCpH 8.4, 50 mM KCl, 7.5 mM MgCl2 , 0.05 mg/ml BSA).
starting from the naturally occurring Met378 throughConditions used for primer annealing, extension, and de-
Asn432 of HIV-1 gag. An Escherichia coli K12 strainnaturation of DNA strands are identical to those pre-
AP401K harboring plasmids pGZ/H6CANC6 or pGZ/viously described (Allen et al., 1995).
NC55-1 was induced for expression with bacteriophagePCR products were transcribed using T7 RNA polymer-
mGP1-2 (gift from S. Tabor), an M13 derivative containingase in vitro in a 200-ml reaction volume (Tuerk and Gold,
the gene for T7 RNA polymerase, as described (Hostom-1990). T7 transcripts were purified from a 6% polyacryl-
sky et al., 1989).amide, 7 M Urea gel and eluted by crushing gel pieces
in a Sodium Acetate/EDTA solution. For each round of
Purification of nucleocapsid p7SELEX, 50 pmol of the selected pool of RNA was phos-
phatased using Calf Intestinal Alkaline Phosphatase
The E. coli cells, harvested 3 hr after induction, were(Biolabs) and 25 pmol was 5* end-labeled using [g-32P]-
resuspended in 50 mM Tris/HCl, pH 8.0, and lysed in aATP with polynucleotide kinase (Boehringer) for 30 min.
microfluidizer (Microfluidics Corp.). After removal of cellKinased RNA was purified and about 150,000 cpm was
debris by centrifugation, the nucleic acids were precipi-used to follow the fraction of RNA retained on nitrocellu-
tated from the soluble lysate by stepwise addition oflose filters during selection. Protein and nucleic acid con-
Polymin P to a final concentration of 0.5%. Powderedditions for selection and elution of RNA from nitrocellu-
ammonium sulfate was added to the supernatant to alose filters were as described (Allen et al., 1995).
final concentration of 40%. Upon removal of pellet by
centrifugation, more ammonium sulfate was added toSelection in the presence of nonamplifiable
the supernatant until its concentration reached 80%. Thecompetitor RNA
pellet was taken up in 50 mM Tris/HCl, pH 8.0, 5 mM 2-
mercaptoethanol, 10% glycerol, and 50 mM NaCl (BufferSelections were done using two buffer conditions
where the only difference between the buffers was the C). After dialysis against buffer C, the sample was ap-
plied to a FPLC MonoQ column (Pharmacia). The flow-concentration of NaCl (Buffer A, 10 mM NaOAc (pH 5.3),
2 mM 2-mercaptoethanol, 0.1 mM ZnCl2 , 5 mM MgCl2 , through fractions were pooled and applied directly to
an FPLC MonoS column (Pharmacia). The protein was200 mM NaCl; Buffer B, 10 mM NaOAc (pH 5.3), 2 mM
2-mercaptoethanol, 0.1 mM ZnCl2 , 5 mM MgCl2 , 400 mM released by a linear gradient of 50 mM –1 M NaCl in
buffer C. The pooled nucleocapsid containing fractionsNaCl). The parent pool (500 pmol) of RNA was used in
the first round of selection along with about 100 fmol of were dialysed against buffer D (25 mM Tris/HCl, pH 8.0,
50 mM NaCl, 2 mM 2-mercaptoethanol, and 0.1 mMg-labeled RNA from the same pool. RNA was recovered
and cDNA synthesized and PCR amplified. In rounds 2 ZnCl2) and concentrated to 1.7 mg/ml.
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Purification of capsid–nucleocapsid fusion protein twice, and chloroform extracted, and the fragments were
precipitated with ethanol.
Soluble lysate of E. coli harboring pGZ/H6CANC-6, pre-
pared as in the NC purification described above, was Chemical and enzymatic modification
applied to a Ni//-NTA-agarose column (Quiagen). The of selected RNAs
column was washed extensively with 20 mM Tris/HCl,
RNAs were partially digested using ribonuclease S1pH 8.0, containing 1 M NaCl, followed by 20 mM Tris/
(0.2 units/reaction). For each enzymatic digestion carriedHCl, pH 8.0. The bound CANC fusion protein was eluted
out with NC present in the reaction mixture, the concen-with a linear gradient of 1 –200 mM imidazole in 20 mM
tration of protein varied from 0.05 mM to 10 mM and theTris/HCl buffer (pH 8.0). The CANC (released at approxi-
amount of RNA used was 4 pmol per reaction. Nucleo-mately 60 mM imidazole concentration) was dialysed
capsid and RNA was incubated together in binding bufferagainst buffer D.
at 377 for 20 min then transferred to ice for 5 min before
adding RNase S1 for an additional 5 min. The RNase S1Cloning and sequencing
was preincubated at 47 before adding to reactions. The
PCR amplified DNA from the round 16 selected-pool mix was phenol extracted three times, chloroform ex-
of RNA was phenol and chloroform extracted and ethanol tracted twice, ethanol precipitated, and stored at 0207.
precipitated. The extracted PCR DNA was digested using Primer extensions (Stern et al., 1988) were done the day
BamHI and HindIII (Biolabs) and subcloned into pUC18. of nuclease treatment to identify positions that are acces-
Ligation was carried out at room temperature for 2 hr, sible to the enzyme.
after which the reaction was phenol and chloroform ex-
tracted and used to electroporate competent cells. In vitro inhibition assay
Twenty-five transformants from the SELEX performed in
The 5* end of the synthetic DNA oligonucleotide,the low salt buffer and 30 from the high salt experiment
Con/, (5*-CAATGACCGCATGGGATCCGTGTGGAAAAT-were picked and their DNAs sequenced.
CTCTAGCAGT-3*) was labeled with [g-32P]ATP using
polynucleotide kinase (Boehringer). Labeled con/ (10Binding assays
nM) was incubated at 377 with equimolar ratio of the
Binding assays were done by adding 5 ml of HIV-1 complementary strand, con0, in binding buffer con-
nucleocapsid p7 protein, at the appropriate concentra- taining various concentrations of NaCl for 6 min and then
tions, to 45 ml of binding buffer (10 mM NaOAc (pH 5.3), run on an 8% native acrylamide gel to determine the salt
2 mM 2-mercaptoethanol, 0.1 mM ZnCl2 , 5 mM MgCl2 , concentration that provides approximately 50% duplex.
100 mM NaCl) on ice, then adding 80,000 cpm of kinased Binding buffer containing 200 mM NaCl converted 40 to
RNA (200 fmol) in a volume of 3 to 4 ml. This mix was 70% labeled con/ to duplex. This buffer was used and
incubated at 377C for 20 min. The reactions were passed the concentration of each oligo was reduced keeping the
over nitrocellulose filters that had been preequilibrated reaction time constant to find an oligo concentration that
in the same buffer. The protein bound filters were would give less than 10% duplex formation under these
washed five times with one milliliter of 50 mM Tris–Cl, conditions.
pH 7.5, solution. Filters were dried and counted in cock- The conditions in the reaction used for the inhibition
tail. The protein used in these experiments was frozen assay were as follows. Four hundred picomoles of each
and thawed only once. Dissociation constants were de- DNA oligo (con//0) was mixed with 10 nM nucleocapsid
termined as previously described (Carey et al., 1983). for 6 min at 377 in binding buffer containing 200 mM
NaCl in a reaction volume of 30 ml. After this time, reac-
Determination of the minimum binding domain tions were stopped by placing on ice and loaded on gel
after 2 min. Gels were run at 250 V for 3.5 hr. In reactionsBoundary determination experiments were carried out
where random RNA was added as inhibitor, the concen-essentially as previously published (Tuerk et al., 1990)
trations ranged from 6500 nM to 9 nM. Where selectedwith the following exceptions. Our transcripts were
RNAs were used, the range was 720 nM to 0.11 nM.treated with calf intestinal alkaline phosphatase (Bio-
labs). For each reaction, 25 pmol of partially hydrolyzed
Synthesis of RNA truncates
RNA was incubated with nucleocapsid protein in binding
buffer in a final reaction volume of 50 ml. Nucleocapsid Primers that anneal at approximately 10 nucleotide
increments from the 3* end of the 400-23 RNA were usedconcentrations were 0.5 1 1009, 1 1 1009, and 5 1 1009
in each case. Reactions were quenched as previously to synthesize cDNAs. Primers and RNAs were heated to
907 and cooled slowly to 457 to anneal and primer exten-described (Chen and Gold, 1994). RNA fragments re-
tained on filters were eluted using 150 ml of 1% SDS/0.3 sion was carried out at 487. cDNAs were then PCR ampli-
fied using the same 3* primers with the original 5* primer.M NaOAc/1 mM EDTA solution, then phenol extracted
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TABLE 1
Sequences of RNAs That Resulted from SELEX Using HIV-1 Nucleocapsid Protein p7
Note. Bases in italics are fixed positions used for PCR amplification. Nucleotides that are highly conserved are underlined. In addition to being
underlined, the fourteen nucleotide block is also in bold face. Numbers to the left of sequences represent the number of isolates bearing this
sequence. All sequences are presented in a 5* to 3* orientation.
The resulting product was used to transcribe 3* truncated These experiments were carried out in duplicates. All
binding curves were done using g-32P-labeled RNA inRNAs. In addition to in vitro transcriptions, the shortest
truncate (T-23) was also made synthetically. binding buffer containing 100 mM NaCl. Dissociation
constants (Kds) ranged from 2 to 6 nM (Fig. 1). Kds of the
two round 16 selected pools of RNA for nucleocapsidRESULTS
protein were likewise under 10 nM (data not shown).
Sequence analysis
The Kd for the initial random pool of RNA in the same
buffer could not be determined since there was noSequencing a total of 55 clones isolated after 16 com-
plete rounds of SELEX resulted in multiple copies of 14 significant binding above background at the highest
protein concentration (1007 M).distinct sequences (Table 1). Each sequence includes a
14-nucleotide block which is nearly identical. This highly Binding affinities were determined for 6 of the 12
conserved 14-base sequence-block occurs at different
positions within the randomized region. Six of the iso-
lates have single-base substitutions within the 14-nucle-
otide sequence-block (Table 1). Five of these are single
base substitutions (U to A) at the ninth position of the
block, while the other is a C to U base change at the
fourteenth position. All other positions in the conserved
block are identical among the clones. Besides the con-
served sequence-block there is no other sequence ho-
mology shared among the selected sequences with the
exception of a highly conserved cytosine at the last posi-
tion of the random region. In general, the conserved se-
quence is located proximal to the 5* end of the random
region.
FIG. 1. Nitrocellulose filter binding curves for clones 400-17 and 400-
23 and for the parent pool of RNA, 30N1. Open circles, 400-17; filledFilter binding studies
squares, 400-23; open squares, 30N1. Nucleocapsid concentrations
The dissociation constants for 12 of the 14 RNA spe- are in molar. These are results from average of duplicate experiments
done in binding buffer containing 100 mM NaCl.cies were determined by nitrocellulose filter binding.
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FIG. 2. Predicted secondary structures of RNAs selected to bind HIV-1 nucleocapsid. Numbers on each structure represent nucleotide positions
from the 5* end. In each case the 5* proximal 23 nucleotides and the 3* terminal 24 nucleotides are fixed. A dot represents noncanonical pairing.
isolates for a precursor fusion protein derived from actions are G-C base pairs. There is good support for
this structure from experiments using structure-sensitivethe HIV-1 gag region [CA-NC; Capsid (p24) fused to
Nucleocapsid (p7)]. The 322 amino acid polypeptide probes and primer extension (Fig. 5). Because all of the
stem regions involve base-pairing with bases that wereproduct, which includes the entire 55 amino acid se-
quence of the NC used in the SELEX experiments, had fixed, there is no comparative evidence to support our
model.no detectable binding affinity for these RNAs (data not
shown). Two possible explanations for this result are
that the RNA binding site of nucleocapsid is blocked in Boundary analysis
the fusion protein, or the conformation of nucleocapsid
Boundary experiments were carried out in order towithin the fusion is altered yielding a protein that lacks
determine the minimum RNA structure required for bind-the RNA binding site. SELEX was carried out using the
ing to HIV-1 nucleocapsid protein. The 5*-end-labeledsame gag fusion protein and the winning ligands from
RNAs were partially alkaline hydrolyzed and the frag-those experiments bear no resemblance to the NC li-
ments were incubated with nucleocapsid protein andgands (Allen, Liss, and Gold, unpublished).
passed over nitrocellulose filters. Fragments with affini-
ties high enough to survive washes were retained. TheseRNA structure analysis
RNAs were eluted from the filters and analyzed on acryl-
RNA transcripts of the individual clones were se- amide gels. In every case, the deletion of nucleotides
quenced directly and entered into the Zuker folding pro- from the 3* end is tolerated up to, but not including, the
gram. The algorithm predicted that all 55 clones folded last nucleotide in the sequence block (Fig. 3). In other
into the same secondary structure. The energy minimiza- words, full-length RNAs and molecules bearing sequen-
tion for each RNA molecule was calculated to be 011 tial deletions from the 3* end are bound by nucleocapsid
kcal/mol or better. The consensus structure was a stem and retained on filters except for deletions into the con-
formed between the first 10 nucleotides at the fixed 5* served 14-nucleotide block (Fig. 3). This indicates that
end and 10 of the 14 nucleotides from the conserved the stem between the 5* end and the nucleotides of the
block with a loop that varied in size from 13 nucleotides 3* end of the conserved block is required for high affinity
(clone 400-23) to 23 nucleotides (clone 400-18). In the binding. When the 3* end is labeled and the same hydro-
center of the 10-bp stem is a 4-base internal bulge whose lysis and binding experiments are carried out, only intact
primary sequence, 5*AACU3*, is highly conserved (Fig. RNAs were retained on filters (data not shown). Thus,
2). The balance of the nucleotides that were originally any deletion at the 5* end results in failure to bind the
randomized are modeled as an unstructured region. The nucleocapsid protein.
highly conserved cytosine at the last position in the ran-
dom region is paired with a G in the 3*-fixed region. Binding studies of RNA truncates
The rest of the 3*-fixed nucleotides fold into two hairpin
structures with the terminal 3* C unpaired. There are The minimum binding domain predicted by the bound-
ary analysis for the RNA identified as 400-23 was usedtwo noncanonical G-U pairs in the consensus structure.
Approximately 75% of the modeled Watson–Crick inter- for further characterization of the RNA binding site. This
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FIG. 3. Autoradiograph showing results from boundary experiments. 17, 400-17; 23, 400-23; 13, 400-13. T1, partial RNase T1 digest; AH, partial
alkaline hydrolysis; lane 1, contains 0.5 1 1009 M nucleocapsid; lane 2, contains 1 1 1009 M nucleocapsid; lane 3, contains 51 1009 M nucleocapsid;
G’s are T1-specific cleavage sites and the numbers are the position in the RNA from the 5* end. Arrows indicate the 3* terminal C in the conserved
14 nucleotide block.
RNA fragment, referred to as T-23, is 37 nucleotides long. 29 (BC48) nucleotides from the 3* end resulted in slight,
though significant decreases in affinity (Fig. 4). RemovalIn addition to this fragment, we made an RNA where the
loop was substituted with a UUCG tetra-loop resulting in of an additional 11 nucleotides (T-23; minimum binding
domain) caused binding to drop drastically. Although T-a fragment 28 nucleotides long (BC2). Both of these RNAs
were synthesized on an Applied Biosystems Model 394 23 binds to the nucleocapsid protein tighter than the
parent pool (30N RNA), its dissociation constant is sur-DNA/RNA synthesizer as well as transcribed in vitro from
PCR products. Neither of the truncates bound the nucleo- prisingly greater than 400-23 (Fig. 4). All truncated RNA
fragments were sequenced directly to confirm their sizecapsid protein as well as the full-length RNA, therefore
other truncates were made and their Kds were deter- and sequence (data not shown). The fragment containing
the tetra-loop (BC2) bound with an affinity similar to thatmined.
Truncated molecules containing the 5* 68, 48, and 37 of T-23.
nucleotides (Fig. 4) were generated by transcribing syn-
Nucleocapsid footprints on the RNAthetic oligonucleotides. Comparing the Kds of these trun-
cates for the nucleocapsid protein to that of the full- The physical binding site of the nucleocapsid protein
length RNA revealed that deletions of nine (BC68) and on one of the SELEX-generated RNAs (400-23) was deter-
mined by nuclease footprinting. Four regions of the RNA
are shielded from digestion by S1 nuclease by varying
concentrations of the nucleocapsid protein. At NC con-
centrations as low as 50 nM, sites in the conserved
AACU bulge are protected from cleavage while remote
nuclease-sensitive sites require up to 10 mM nucleocap-
sid to display protection (Fig. 5). Nucleocapsid footprints
that are observed at high concentrations are seen both
5* and 3* of the bulge. If protein–protein interactions are
important for binding to the low affinity sites, then the
highly conserved four base bulge may serve as the nucle-
ation site for cooperative binding. Our results are consis-
tent with the estimated occlusion size of seven to eight
FIG. 4. Nitrocellulose filter binding curves for mature 400-23 RNA, nucleotides for HIV nucleocapsid (L. Henderson, per-
truncated 400-23 RNAs and 30N1 RNA. open circle, mature 400-23 sonal communication). The apparent binding of multiple
RNA; closed square, 400-23 minus 9 nucleotides from the 3* end (BC68); proteins to each RNA might explain the decreased affini-
open squares, 400-23 minus 29 nucleotides from the 3* end (BC48);
ties observed for the RNAs when they are truncated. Thediamonds, 400-23 minus 40 nucleotides from the 3* end (T-23); filled
binding of the longer RNAs could be enhanced eithercircles, 30N1 RNA. Nucleocapsid concentrations are in molar. Binding
reactions were carried out in binding buffer containing 100 mM NaCl. through cooperative protein binding or by an increase in
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FIG. 5. (A) Autoradiograph showing structure-specific cleavage of 400-23 by S1 and multiple nucleocapsid protection sites. C, U, A, and G are
the sequence of the RNA. 0, blank lane; K, minus S1 control; 1, no NC control; 2, 50 nM NC; 3, 100 nM NC; 4, 500 nM NC; 5, 1 mM NC; 6, 2 mM
NC; 7, 4 mM NC; 8, 10 mM NC. (B) Secondary structure cartoon showing sites of protection. Arrows point to sites that are protected from S1 nuclease
cleavage by NC. The order of binding based on concentration-specific protections is indicated.
the filter retention efficiency brought about by multiple Annealing assays, as described above, were carried
out in the presence of 30N, 400-17, and 400-23 RNAs toproteins binding to a single RNA.
determine the extent to which they inhibited the function
In vitro inhibition of annealing function of the nucleocapsid protein. All three RNA samples were
able to inhibit HIV-1 nucleocapsid protein-dependent an-If the RNA ligands are binding a site on NCp7 that is
nealing, but the two selected RNAs inhibited at concen-used for substrate recognition, then the ligands should
trations which were orders of magnitude lower than thatact as inhibitors. An assay for one of the proposed activi-
of the parent pool of RNA (Fig. 7). It took concentrationsties of nucleocapsid, stimulation of nucleic acid anneal-
of 30N RNA of 722 nM or greater to inhibit the annealinging, was developed to test the inhibition efficiency of the
activity of nucleocapsid in binding buffer containing 100ligands. Complementary nucleic acids, con/ and con0,
mM NaCl. For clones 400-17 and 400-23, the extent ofare converted to the con//0 double-stranded form in 6
inhibition was much greater. 400-17 was able to inhibitmin when nucleocapsid is present in the reaction at 100
approximately 50% of the annealing activity of nucleocap-nM or greater (Fig. 6). Nucleocapsid concentrations of
sid at a concentration of 0.5 nM, while the Ki for 400-2310 nM result in about a 60% conversion while 1 nM
was 3 nM (Fig. 7). The observation of Ki’s for these ligandsnucleocapsid results in a mild increase in double-
that are lower than their observed Kds might be explainedstranded DNA formation above the minus-nucleocapsid
by the apparent cooperative binding observed in the foot-background level.
printing experiments above, as a single ligand could bind
and inhibit multiple proteins.
DISCUSSION
As a first step toward understanding the RNA substrate
binding specificity of the HIV-1 nucleocapsid protein p7,
we generated RNA ligands to the viral protein using the
SELEX protocol. All of the ligands that resulted from the
selection contained a highly conserved 14-nucleotide
block. Computer modeling and structure probing experi-
FIG. 6. Autoradiograph showing stimulation of annealing by HIV-1 ments are consistent with the RNAs adopting a second-
nucleocapsid. Lane 1, end-labeled con/ alone; lane 2, equimolar ratio ary structure comprising two 5-bp stems with a 4-base
of con/ and con0; lane 3, con/, con0, and 100 nM nucleocapsid;
internal bulge of the consensus sequence 5*-AACU-3*.lane 4, con/, con0, and 10 nM nucleocapsid; lane 5, con/, con0,
The invariance of the structural motif among the selectedand 1 nM nucleocapsid. ss, single-stranded con/; ds, double-stranded
con//0. ligands suggests that it is the primary recognition site
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FIG. 7. Autoradiograph showing in vitro inhibition of HIV-1 nucleocapsid annealing function. Lanes labeled Con//Con0 have both complementary
strands in the absence of nucleocapsid; Con//Con0/NC, contains nucleocapsid but no RNA. All lanes labeled with a RNA concentration also
contains con/, con0, and nucleocapsid (see methods). 7A, 30N1 RNA; 7B, 400-17; 7C, 400-23. RNA concentrations are given in nanomolar.
for the nucleocapsid protein. This idea is corroborated
by boundary and protein footprinting data. The fact that
all of the ligands utilized the 5* most nucleotides in the
RNA molecules does not necessarily reflect a need for
the structure to occur at the 5* terminus of an RNA in
order to generate high affinity binding. Molecules using
the 5*-fixed region to form one-half of the hairpin are
expected to be more than a thousand-fold more prevalent
in the initial RNA population than those molecules that
form the structure using only nucleotides within the ran-
dom region.
Two regions of the HIV-1 genome that are thought to
interact with the nucleocapsid protein, the primer binding
site (PBS) where tRNA3
Lys anneals prior to cDNA synthe-
sis and a domain implicated in encapsidation (Aldovini
and Young, 1990; Clavel and Orenstein, 1990), were
searched for potential nucleocapsid binding sites. AACU
sequences or minor variations of this sequence were
sought out within or near these two areas, and the sur- FIG. 8. Three potential secondary structures from the HIV-1 viral
rounding sequences were checked for there capacity to genome that are similar to the motif that was identified as a high affinity
site for the nucleocapsid protein. The numbers indicate the nucleotidebase-pair to form helices on either side of the AACU.
position relative to the transcriptional start site of the HIV-1 genome.The search identified several primary sequences that
The primer binding site spans the RNA from positions 107–125; thecould form structures that were very similar to the SELEX-
encapsidation domain is suspected to occur between nucleotides 223
generated consensus (Fig. 8). We have no physical evi- and 337 (nucleotide positions taken from Ratner et al., 1985). Structures
dence for the existence of these structures in the PBS A and B flank the primer binding site, while structure C is located in
the putative encapsidation region.or encapsidation region. However, it is tempting to spec-
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L. E., and Rein, A. (1990). Noninfectious human immunodeficiencyulate on a model where nucleocapsid protein binds these
virus type 1 mutants deficient in genomic RNA. J. Virol. 64, 3207–elements during the life cycle of the virus and exert its
3211.
effects on the various NC-mediated events. In our model, Gorelick, R. J., Chabot, D. J., Rein, A., Henderson, L. E., and Arthur, L. O.
nucleocapsid protein binds these structures and localize (1993). The two zinc fingers in the human immunodeficiency virus
the involved components to these regions of the genomic type 1 nucleocapsid protein are not functionally equivalent. J. Virol.
67, 4027–4036.RNA. Since our SELEX-generated ligands are inhibitors
Harrison, G. P., and Lever, A. M. L. (1992). The human immunodefi-of the annealing activity of the NC in vitro, these RNAs
ciency virus type 1 packaging signal and major splice donor regioncould prove to be useful therapeutic agents. It would be
have a conserved stable secondary structure. J. Virol. 66, 4144–4153.
interesting to learn about the effects of these ligands on Hostomska, Z., Matthews, D. A., Davies, J. F. II., Nodes, B. R., and Hos-
other NC-mediated activities. tomsky, Z. (1991). Proteolytic release and crystallization of the RNase
H domain of human immunodeficiency virus type 1 reverse tran-
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